---
layout: page
title:  "Title of Lab News 4"
teaser: "short summary of lab news 4"
header:
    image_fullwidth: "ampp_header.png"
breadcrumb: true
---

Results of the Phase 2 Consortium trial of ibrutinib in relapsed or refractory follicular lymphoma ([NCT01849263](https://clinicaltrials.gov/show/NCT01849263?link_type=CLINTRIALGOV&access_num=NCT01849263&sso-checked=true)) have been published online through the journal Blood. Genomic analysis led by Griffith lab postdoc, Felicia Gomez, identified CARD11 mutations as predictors of poor treatment response.

<div class="row">
    <div class="small-12 columns">
        <img src="/assets/img/news/CARD11_figure_8.png">
    </div>
</div>
<br>
Read the article: [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29074501)] [[Journal website](http://www.bloodjournal.org/content/early/2017/10/25/blood-2017-09-804641?papetoc=&sso-checked=true)]
